Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors

Alessandro Busca, Anna Novarino, Paolo de Fabritiis, Alessandra Picardi, Massimo Zeuli, Franco Locatelli, Oscar Bertetto, Michele Falda

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors. Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine (90 mg/m 2) and TBI 200 cGy. Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease (median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation. Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.

Original languageEnglish
Pages (from-to)171-177
Number of pages7
JournalHematology
Volume11
Issue number3
DOIs
Publication statusPublished - Jun 2006

Keywords

  • Allogeneic stem cell transplantation
  • Graft versus tumor effect
  • Nonmyeloablative regimen
  • Solid tumors

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors'. Together they form a unique fingerprint.

Cite this